Drug Profile
House dust mite allergy immunotherapy - Wolwo Bio-pharmaceutical
Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Wolwo Bio-pharmaceutical
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Atopic-dermatitis in China (Sublingual, Drops)